Drug Trial Radar · NCT03000257
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Apr 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
182
Actual
Start
Dec 14, 2016
Primary completion
Mar 29, 2022
Study completion Mar 29, 2022
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 22, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab. This study will also evaluate the safety and tolerability of budigalimab in combination with Rovalpituzumab Tesirine and budigalimab in combination with venetoclax. The study will consist of 3 parts: budigalimab monotherapy dose escalation and expansion, budigalimab in combination with Rovalpituzumab Tesirine and budigalimab in combination with venetoclax.
Conditions
- Advanced Solid Tumors
Interventions
VenetoclaxDrug
Tablet taken orally
Rovalpituzumab TesirineDrug
Intravenous infusion
ABBV-181Drug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Recommended Phase 2 Dose (RPTD) for BudigalimabTime frame: Up to 6 months
- Part 1: Maximum tolerated dose (MTD) of BudigalimabTime frame: Up to 6 months
- Part 1 and Part 3: Terminal Half-life (t1/2) of BudigalimabTime frame: Up to 4 Weeks
- Part 1 and Part 3: Maximum Observed Serum Concentration (Cmax) of BudigalimabTime frame: Up to 12 Weeks
- Part 1 and Part 3: Time to Cmax (Tmax) of BudigalimabTime frame: Up to 12 Weeks
- Part 1 and Part 3: Area Under the Serum Concentration Time Curve from Time 0 to Last Measurable Concentration (AUCt) of BudigalimabTime frame: Up to 12 Weeks
- Part 2: Recommended Phase 2 Dose (RPTD) and Schedule for Budigalimab and Rovalpituzumab Tesirine CombinationTime frame: Up to 6 Months
- Part 3: Recommended Phase 2 Dose (RPTD) and Schedule for Budigalimab and Venetoclax Combination.Time frame: Up to 6 Months
- Part 3: Maximum Observed Serum Concentration (Cmax) for VenetoclaxTime frame: Up to 12 Weeks
- Part 3: Area Under the Serum Concentration Time Curve from Time 0 to 24 Hours Post-dose (AUC(0-24)) of VenetoclaxTime frame: Up to 12 Weeks
- Part 3: Time to Cmax (Tmax) of VenetoclaxTime frame: Up to 12 Weeks
- Part 1, Part 2, Part 3: Number of Participants with Adverse EventsTime frame: From first dose of study drug until 90 days following last dose of study drug (up to 24 months)
Locations
26 sites in 10 countries. Site status is shown where the registry gives one.
Moores Cancer Center at UC San Diego /ID# 157374
La Jolla, California
The University of Chicago Medical Center /ID# 157375
Chicago, Illinois
Carolina BioOncology Institute /ID# 157376
Huntersville, North Carolina
South Texas Accelerated Research Therapeutics /ID# 157378
San Antonio, Texas
Virginia Cancer Specialists - Fairfax /ID# 157377
Fairfax, Virginia
Blacktown Hospital /ID# 167386
Blacktown, New South Wales, Australia
St Vincent's Hospital Melbourne /ID# 167552
Fitzroy Melbourne, Victoria, Australia
Linear Clinical Research /ID# 170797
Nedlands, Western Australia, Australia
Medizinische Universitaet Graz /ID# 168752
Graz, Styria, Austria
Universitair Ziekenhuis Antwerpen /ID# 170702
Edegem, Antwerpen, Belgium
UZ Gent /ID# 170881
Ghent, Oost-Vlaanderen, Belgium
Cross Cancer Institute /ID# 167603
Edmonton, Alberta, Canada
Docrates Cancer Center /ID# 166838
Helsinki, Finland
Tampere University Hospital /ID# 166839
Tampere, Pirkanmaa, Finland
Institut Bergonie /ID# 162662
Bordeaux, Gironde, France
Institut du Cancer de Montpellier - Val d'Aurelle /ID# 163999
Montpellier, Herault, France
Centre Leon Berard /ID# 162660
Lyon, Rhone, France
Institut Gustave Roussy /ID# 162753
Villejuif, Val-de-Marne, France
National Cancer Center Hospital East /ID# 166433
Kashiwa-shi, Chiba, Japan
National Hospital Organization Kyushu Cancer Center /ID# 206229
Fukuoka, Fukuoka, Japan
National Cancer Center Hospital /ID# 166279
Chuo-ku, Tokyo, Japan
Hospital Universitario Fundacion Jimenez Diaz /ID# 163862
Madrid, Spain
Hospital Universitario HM Sanchinarro /ID# 163861
Madrid, Spain
Hospital Clinico Universitario de Valencia /ID# 163925
Valencia, Spain
National Taiwan University Hospital /ID# 163997
Taipei, Taiwan
Taipei Medical University Hospital /ID# 163998
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.